Unprecedented Response Rates in Non-Responsive, Non-Muscle Invasive Bladder Cancer
LAS VEGAS — Patients with high-risk, treatment-unresponsive non-muscle invasive bladder cancer (NMIBC) had an unprecedented response rate and disease-free survival (DFS) with an investigational intravesical treatment system, data from an ongoing trial showed. Complete responses (CR) occurred in 82.4% of 85 patients treated with TAR-200, a system that delivers gemcitabine directly into the bladder. The […]